On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19

The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, an...

Full description

Bibliographic Details
Main Authors: Thilo Gambichler, Judith Reuther, Christina H Scheel, Jürgen Christian Becker
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001145.full
id doaj-f482991f5d1249cca04a2b2bb2bea1c7
record_format Article
spelling doaj-f482991f5d1249cca04a2b2bb2bea1c72021-07-13T15:00:10ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-07-018210.1136/jitc-2020-001145On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19Thilo Gambichler0Judith Reuther1Christina H Scheel2Jürgen Christian Becker3Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, GermanySkin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, GermanySkin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, GermanyTranslational Skin Cancer Research, German Cancer Consortium (DKTK), Dermatology, University Duisburg-Essen, Essen, GermanyThe present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.https://jitc.bmj.com/content/8/2/e001145.full
collection DOAJ
language English
format Article
sources DOAJ
author Thilo Gambichler
Judith Reuther
Christina H Scheel
Jürgen Christian Becker
spellingShingle Thilo Gambichler
Judith Reuther
Christina H Scheel
Jürgen Christian Becker
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Journal for ImmunoTherapy of Cancer
author_facet Thilo Gambichler
Judith Reuther
Christina H Scheel
Jürgen Christian Becker
author_sort Thilo Gambichler
title On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
title_short On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
title_full On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
title_fullStr On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
title_full_unstemmed On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
title_sort on the use of immune checkpoint inhibitors in patients with viral infections including covid-19
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-07-01
description The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.
url https://jitc.bmj.com/content/8/2/e001145.full
work_keys_str_mv AT thilogambichler ontheuseofimmunecheckpointinhibitorsinpatientswithviralinfectionsincludingcovid19
AT judithreuther ontheuseofimmunecheckpointinhibitorsinpatientswithviralinfectionsincludingcovid19
AT christinahscheel ontheuseofimmunecheckpointinhibitorsinpatientswithviralinfectionsincludingcovid19
AT jurgenchristianbecker ontheuseofimmunecheckpointinhibitorsinpatientswithviralinfectionsincludingcovid19
_version_ 1721305334989979648

Similar Items